Madola masauzande ambiri amankhwala aku India a COVID-19 agulitsidwa?Chenjerani!

1.Madola masauzande ambiri amankhwala aku India a COVID-19 agulitsidwa?Chenjerani!

Posachedwapa, mutu wonena za "COVID-19 mankhwala aku India amtundu wamba adagulitsidwa masauzande a ma yuan m'bokosi" adawonekera pamndandanda wodziwika bwino wamabulogu.Mankhwala ena adagulidwa m'malo mwa China News Network, ndipo katunduyo anali atagulitsidwa, kotero kunali koyenera kuwasungitsa pasadakhale sabata.Madokotala amakumbutsa kuti mankhwala sayenera kugulidwa kudzera m'njira zosavomerezeka.Kuphatikiza apo, magulu omwe sali pachiwopsezo chachikulu safunikira kugwiritsa ntchito mankhwala apakamwa a COVID-19.

Mtengo woyambirira wa bokosi la mankhwala ndi 2300 yuan, ndipo mtengo wogula ku India ndi 1600 yuan.

"Tsopano maoda asungidwa kwathunthu."Othandizira angapo aku India ogula mankhwala adauza chinanews.com kuti mankhwala awo a Pfizer COVID-19 oral Paxlovid agulitsidwa posachedwa.Ngati ndi kotheka, amatha kulipira ndalamazo poyamba, ndipo katunduyo akhoza kuperekedwa sabata imodzi, kapena mwezi wamawa pang'onopang'ono.

Ngati mawu oti "COVID-19 India", "COVID-19 generic drug" ndi zina zotero akulowa pa nsanja ya e-commerce, ogula atha kupeza mwachangu zambiri za othandizira ogulawa, koma nthawi zambiri amafunikira kuwonjezera abwenzi a WeChat, ndi ndiye dziwitsani za katunduyo ndi zofunika kugula.

Mankhwala amtundu wa Paxlovid omwe amagulitsidwa ndi othandizirawa akuphatikiza Primovir muzopaka zobiriwira ndi Paxista m'matumba abuluu.Yoyamba imapangidwa ndi Astrica, kampani yaku India, pomwe yotsirizirayi imapangidwa ndi Azista, wocheperako ku Indian pharmaceutical Enterprise Hetero.Pakadali pano, Primovir yokhala ndi zopangira zobiriwira yasiya kupanga, ndipo Paxista yokhayo yokhala ndi zopaka zabuluu ndiyomwe ikugulitsidwabe.

Wothandizira wina adalengeza kuti mtengo wamakalata apanyumba ndi yuan 1600 pabokosi lililonse, ndipo makalata akunja akunja anali 1200 yuan pabokosi, 400 yuan otsika mtengo.Mtengo wogula wa Paxlovid ku China ndi 2300 yuan pabokosi lililonse.

Mankhwalawa ndi ovuta kugula pakali pano.Malinga ndi kugula kwa wothandizira pamwambapa, kusungitsa malo ndikovomerezeka, ndipo makalata achindunji aku India afika ku China mkati mwa masiku 15-20.Ananenanso kuti munthu aliyense angogula mabokosi awiri okha.

Madokotala amakumbutsa: Ndizovuta kusiyanitsa zoona ndi zabodza.Khalani tcheru

M'malo mwake, Paxlovid wakhala akugwiritsidwa ntchito pochiza matenda a COVID-19 ku China, koma amagwiritsidwa ntchito kwambiri m'zipatala zina zosankhidwa ndipo amafuna chilolezo chamankhwala adotolo.Sizipatala zonse zili ndi mankhwalawa.

Ndikoyenera kudziwa kuti mankhwala ena a generic omwe amagulitsidwa mwachisawawa amatha kugulidwa popanda ngakhale kupereka mankhwala.Pankhani imeneyi, madokotala akatswiri amakumbutsa aliyense kukhala tcheru.

"Monga madotolo odziwa ntchito, sitilimbikitsa kugula zokopa zakunja, chifukwa ndizovuta kusiyanitsa zowona ndi zabodza."Zhang Jiming, wachiwiri kwa mkulu wa National Infectious Diseases Medical Center komanso dotolo wamkulu, pulofesa ndi woyang'anira chipatala cha Huashan chogwirizana ndi Fudan University, adauza chinanews.com kuti odwala ena omwe adawafunsa kapena mabanja awo adagula zinthu zotsanzira mwachinsinsi, ndipo adadandaula kuti akugula mankhwala abodza.Ananenanso kuti zinali zovuta kuonetsetsa kuti mankhwala opangidwa ndi generic amachokera ku gwero ndi momwe amasungirako mankhwala pogula mankhwala opangidwa ndi generic kuchokera kunja.

Zhang Jiming adalengeza kuti mankhwala apakamwa a COVID-19 amagwiritsidwa ntchito makamaka m'magulu omwe ali pachiwopsezo chachikulu kuti apewe matenda oopsa, ndipo amatha kugwira ntchito pokhapokha atagwiritsidwa ntchito koyambirira.Magulu omwe sali pachiwopsezo chachikulu sayenera kuthamangira kukagula, ndipo nkhanza zingayambitse kukana mankhwala.Ndizosafunikiranso kuchipatala, chifukwa odwala ambiri amakhala opanda zizindikiro kapena ofatsa, ndipo matendawa amakhala ochepa.

Adauza atolankhani.com kuti, malinga ndi momwe zinthu zilili ku Shanghai, zipatala zazikulu, zipatala zosankhidwa ndi COVID-19 ndi mabungwe ena azachipatala nthawi zambiri amakhala ndi mankhwala enaake odana ndi COVID-19, omwe amagwiritsidwa ntchito ndi magulu omwe ali pachiwopsezo chachikulu omwe amakwaniritsa zomwe akuwonetsa. kudwala COVID-19, pofuna kupewa matenda oopsa komanso kuchepetsa kuchuluka kwaimfa.

Kuphatikiza apo, malinga ndi malipoti atolankhani, ogwira ntchito zamalamulo amakumbutsa kuti mankhwala amtundu wa Indian COVID-19 omwe amagulitsidwa pa intaneti sanavomerezedwe ku China.Pansi pa lamulo laposachedwa la Drug Administration Law of the People's Republic of China, ngakhale kuti mankhwala omwe adalembedwa kunja koma sanavomerezedwe ku China samadziwikanso ngati mankhwala abodza, ogwiritsira ntchito adzakumanabe ndi zilango zoyang'anira pakutumiza mankhwala osokoneza bongo kuchokera kunja.

2.Xinlitai wapita!Kugwira mitundu iwiri ya 1 biliyoni, mitundu 11 ya mankhwala atsopano a Gulu loyamba.

Posachedwa, mapaipi a Xinlitai R&D apita patsogolo.Mapiritsi amtundu woyamba wa SAL0133 agwiritsidwa ntchito pachipatala.Zotsatira zowunikira zowerengera zapezeka kuchokera ku mayeso achipatala a Phase Ib a PCSK9 monoclonal antibody.Kuyambira 2022, Xinlitai adafunsira IND/NDA pamankhwala 7 otsogola, ndipo kafukufuku wamakono ndi chitukuko chakhala chikulimbikitsidwa pang'onopang'ono.Pakalipano, Xinlitai ili ndi mitundu iwiri ya 1 biliyoni, 22 yomwe yawunikidwa (8 ndiyo yoyamba);Mankhwala 21 akufufuzidwa, 6 mwa iwo ali mu chipatala cha NDA kapena Phase III, ndipo njira yatsopanoyi yalowa mu nthawi ya ndalama.

Mankhwala a Oral COVID-19 Akuwoneka!Xinlitai Alowa M'dera la COVID-19

Pa Disembala 20, Xinlitai adalengeza kuti kugwiritsa ntchito kwachipatala kwa SAL0133, mankhwala ang'onoang'ono ang'onoang'ono opangidwa ndi kampaniyo, adavomerezedwa ndi State Food and Drug Administration.SAL0133 ndi choletsa champhamvu cholimbana ndi novel coronavirus 3CL protease (3CLpro) inhibitor yopangidwa mwaokha ndikupangidwa ndi kampani yomwe ili ndi ufulu wodziyimira pawokha wazinthu zaluso.Pakadali pano, chizindikiritso chachipatala chomwe chikuyenera kupangidwa ndikuchiza chibayo cha anthu achikulire ofatsa/wamba (COVID-19).

3CLpro imagwira ntchito yofunikira pakugawanika kwa RNA kwa coronavirus yatsopano, makamaka mu gawo lobwerezabwereza pambuyo poti kachilomboka kalowa mu cell, kuletsa ntchito ya 3CLpro protease, yomwe imatha kuletsa kubwereza kwa kachilomboka ndikukwaniritsa udindo wa anti novel coronavirus.

SAL0133 ili ndi machitidwe omveka bwino, ndipo ili ndi mphamvu yolimbana ndi COVID-19.Zikuyembekezeka kuti siziyenera kuphatikizika ndi CYP3A4 inhibitor ritonavir, ndipo chiwopsezo chomwe chingathe kuyanjana ndi mankhwala ndi chochepa;Akuyembekezeka kukwaniritsa kugwiritsa ntchito mankhwala amodzi kamodzi patsiku ndikuwongolera kutsatira kwa odwala.Ngati ingapangidwe bwino ndikuvomerezedwa kuti igulitse, idzapatsa odwala kusankha mankhwala atsopano kuti akwaniritse zosowa zachipatala zomwe sizikugwirizana nazo.

Kafukufuku ndi chitukuko cha 3CL chandamale cha anti COVID-19 oral molecule mankhwala ang'onoang'ono akopa chidwi.Pakadali pano, Pfizer's Paxlovid yokha ndiyomwe idavomerezedwa kutsatsa padziko lonse lapansi.Mabizinesi opitilira 10 azachipatala komanso mabungwe ofufuza zasayansi akhala akuchita kafukufuku ndi chitukuko cha 3CL chandamale cha anti COVID-19, kuphatikiza FB2001 ya Frontier Biology, VV993 ya Junshi Biology/Wangshan Wangshui, SIM0417 ya Pioneer Pharmaceutical, RAY1216 Pharmaceutical mapiritsi a Zhonggutical GST-HG171 ya Guangshengtang, etc.

Ndi mitundu iwiri yayikulu 1 biliyoni yomwe ili m'manja, mankhwala 7 otsogola chaka chino alandila kupita patsogolo kwatsopano

Kumapeto kwa chaka cha 2022, monga woyimira kusintha kwa R&D m'makampani opanga mankhwala, Xinlitai adapeza njira yakeyake yachitukuko mokakamizidwa ndikusintha.

M'magawo atatu oyambirira a 2022, ndalama za kampaniyo zinali 2.548 biliyoni, ndikukula chaka ndi chaka ndi 16.5%, ndipo phindu lake linali 539 miliyoni yuan, ndikukula kwa chaka ndi 37.64%.Kuchita bwino kunayala maziko olimba a chitukuko chotsatira.Kampaniyo ikuyembekeza kuti mu 2022, Taijia (mapiritsi a clopidogrel bisulfate) adzalandira pafupifupi 1 biliyoni ya yuan, ndipo Sinritan (mapiritsi aalisartan) adzalandira pafupifupi 900 miliyoni yuan mpaka 1 biliyoni.Kampaniyo ili ndi mitundu 22, 8 mwa iyo ndi yoyamba ku China.

Mu 2019, mitundu yayikulu ya Xinlitai, Taijia, idataya mwayi pakugula kwapakati kwa 4 + 7, zomwe zidakakamiza Xinlitai kuti asinthe.Mu lipoti la pachaka la 2019, Xinlitai adalengeza kuti "paipi yofufuzira idzakonzedwa bwino, ndipo mapulojekiti odana ndi zotupa zamoyo ndi maantibayotiki m'magawo ena azachipatala adzathetsedwa".Mu 2020, kuti apititse patsogolo kukhathamiritsa kwa payipi pansi pa kafukufuku ndi kuyang'ana pa R&D ndi kukwezedwa kwa zinthu zatsopano, Xinlitai adasamutsa ufulu ndi zokonda za dapoxetine hydrochloride, erlotinib hydrochloride, rivasaban ndi mapulojekiti ena, ndikulandila ndalama zosinthira.

Pambuyo pa zosintha zina, pakadali pano, mapaipi amankhwala amtundu wa Xinritai amangokhala ndi pulogalamu yotsatsa ya Class 4 yotsanzira mapiritsi a sodium a Sakubatrovalsartan omwe akuwunikiridwa, komanso kugwiritsa ntchito kuwunika kosasinthika kwa cefuroxime sodium wa jakisoni ndi cefotaxime sodium wa jakisoni akuwunikiridwa.Ndikoyenera kunena kuti kuyambira Julayi 2019, Xinlitai sanalembetse mankhwala atsopano kwazaka zopitilira 3, ndipo amayang'ana kwambiri zaukadaulo komanso kafukufuku.

Kuyambira 2022, Xinlitai yapita patsogolo mosalekeza pakufufuza ndi kupanga mankhwala atsopano.Pa Januware 4, 2022, kugwiritsa ntchito pamndandanda wa mapiritsi a CINRITAI a HIF-PHI inhibitor Enasitar kudapangidwa ndi CDE;Pambuyo pake, Kampani idapereka mafomu ofunsira mankhwala atsopano asanu a Gulu loyamba, omwe ndi recombinant human neuromodulin-1 anti HER3 antibody fusion protein injection, mapiritsi a SAL0112, jakisoni wa SAL008, mapiritsi a SAL0119 ndi mapiritsi a SAL0133;Pa November 3, kalasi yatsopano ya 2.3 inapititsa patsogolo mapiritsi a alisartan ndi amlodipine a SINRITAI adapereka fomu yolembera, yomwe ikuyembekezeka kupanga mgwirizano wamagulu ndi gulu la 1.1 la antihypertensive mankhwala SINRITAI.

JinDun Medicalali ndi mgwirizano wanthawi yayitali wofufuza zasayansi komanso kulumikiza ukadaulo ndi mayunivesite aku China.Ndi chithandizo chamankhwala cholemera cha Jiangsu, ili ndi ubale wautali wamalonda ndi India, Southeast Asia, South Korea, Japan ndi misika ina.Imaperekanso ntchito zamsika ndi zogulitsa munjira yonse kuyambira apakatikati mpaka kumaliza API.Gwiritsani ntchito zomwe zasonkhanitsidwa za Yangshi Chemical mu chemistry ya fluorine kuti mupereke ntchito zapadera zosinthira makonda kwa anzanu.Perekani njira zatsopano zogwirira ntchito ndi ntchito zofufuza zonyansa kwa makasitomala.

JinDun Medical akuumirira pakupanga gulu lokhala ndi maloto, kupanga zinthu mwaulemu, mosamala, mosamalitsa, ndikupita zonse kuti mukhale bwenzi lodalirika komanso bwenzi lamakasitomala! akatswirimakonda kupanga mankhwala(CMO) ndi othandizira opangira mankhwala a R&D ndi kupanga (CDMO).Jindun akutsagana nanu kukacheza ndi COVID-19.